Jamjoom Pharmaceuticals Factory Co. announces its Annual Financial results for the period ending on 2024-12-31
| Element List | Current Year | Previous Year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 1,318.48 | 1,100.82 | 19.77 | ||
| Gross Profit (Loss) | 820.5 | 703.84 | 16.57 | ||
| Operational Profit (Loss) | 381.09 | 313.3 | 21.64 | ||
| Net profit (Loss) | 356.52 | 292.4 | 21.93 | ||
| Total Comprehensive Income | 303.28 | 258.07 | 17.52 | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 1,490.61 | 1,404.33 | 6.14 | ||
| Profit (Loss) per Share | 5.1 | 4.2 | |||
| All figures are in (Thousands) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Thousands) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current year compared to the last year | Revenue for the current year has increased by 19.8% compared to the previous year, driven by successful strategic initiatives to expand sales in key markets and therapeutic areas. This growth was further supported by new product launches and enhanced manufacturing capabilities, driven by newly launched facilities in Egypt and KSA. Additionally, overall pharmaceutical market expansion contributed to the strong top-line performance. |
| The reason of the increase (decrease) in the net profit during the current year compared to the last year is | Net profit for the current year increased by 21.9% compared to the previous year, primarily driven by strong revenue growth and an effective strategy to optimize profitability and operating cost control. Additionally, a profit contribution from the joint venture in Algeria supported earnings. However, this was partially offset by the negative foreign exchange impact from the EGP devaluation. |
| Statement of the type of external auditor's report | Unmodified opinion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | None |
| Reclassification of Comparison Items | Certain comparative amounts have been reclassified or re-presented during the current year for better presentation. |
| Additional Information | The Company’s financial position continued to be strong with zero debt.
As at 31 December 2024, cash balance was SAR 261.7 million, which represented a decrease of 8.0% compared to the balance at 31 December 2023. This demonstrates the Company's ability to sustain the strength of its core operations and generate liquidity whilst returning value to shareholders through dividend distributions.
Please refer to the attached Press Release for more information on the FY 2024 results. |
| Attached Documents |  |
Comments